Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1

checkorphan
Learn more about:
Myotonic Dystrophy 1
Related Clinical Trial
Effects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1 DMCRN-02-001: Assessing Pediatric Endpoints in DM1 Myotonic Dystrophy Type 1 and Resistance Exercise Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Biomarker Development for Muscular Dystrophies Extracellular RNA Biomarkers of Myotonic Dystrophy Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 Myotonic Dystrophy – Vascular and Cognition Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Open Label Study in Adolescents and Children With Myotonic Disorders European Home Mechanical Ventilation Registry Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Efficacy and Safety of DHEA for Myotonic Dystrophy Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 Venous Thromboembolism in DM1 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Observational Prolonged Trial in Myotonic Dystrophy Type 1 Venous Thromboembolism in Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 1 Aerobic Exercise Study Multicenter Observational Study of Myotonic Dystrophy Type 1 DM1 Heart Registry – DM1 Respiratory Registry

Brief Title

Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1

Official Title

Effects of a Multiple Component Training Program on Muscles, Maximal Muscle Strength, Endurance and Functional Performance in Adults With Myotonic Dystrophy Type 1: A Pilot Study

Brief Summary

      A strength and endurance training program was conducted in adults with myotonic dystrophy
      type 1 (DM1). Participants underwent a 12-week/18-session supervised training program
      consisted of 6 exercises: elbow flexion/extension, shoulder horizontal adduction, leg press,
      and knee flexion/extension. To offer a complete training program aimed at improving function
      it was divided: the first 6 weeks were dedicated to strength-training, whereas the following
      weeks focused on endurance-training. To evaluate the effects of the training program,
      participants completed maximal strength, endurance and functional evaluations. Volunteers
      could also add a muscle biopsy at the beginning and the end of the program to evaluate
      physiological parameters.

Study Type

Interventional

Primary Outcome

Change in maximal muscle strength in the knee extensors measured by quantified muscle testing

Secondary Outcome

 Change in 6 minute walking test disance

Condition

Myotonic Dystrophy 1

Intervention

Training program

Study Arms / Comparison Groups

 Training program
Description:  12-week strength and endurance training program

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Other

Estimated Enrollment

11

Start Date

July 23, 2013

Completion Date

December 13, 2013

Primary Completion Date

December 13, 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Adults with DM1

          -  Walk without technical aid

          -  Muscle impairment rating scale (MIRS) of 3 or 4

        Exclusion Criteria:

          -  Severe musculoskeletal disorders

          -  Any medical contraindication to physical exercise

          -  Any medical contraindication to muscle biopsies for the biopsy volunteers

Gender

All

Ages

20 Years - 60 Years

Accepts Healthy Volunteers

No

Contacts

Cynthia Gagnon, Ph.D., ,

Location Countries

Canada

Location Countries

Canada

Administrative Informations

NCT ID

NCT04001920

Organization ID

2013-008

Responsible Party

Sponsor-Investigator

Study Sponsor

Cynthia Gagnon

Collaborators

 Fondation du Grand défi Pierre Lavoie

Study Sponsor

Cynthia Gagnon, Ph.D., Principal Investigator, Université de Sherbrooke

Verification Date

June 2019